FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138906968> ?p ?o ?g. }

• W2138906968 endingPage "252" @default.
• W2138906968 startingPage "231" @default.
• W2138906968 abstract "A systematic review of chemotherapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for the evaluation of the scientific literature are described separately (Acta Oncol 2001; 40: 155-65). This synthesis of the literature on chemotherapy in patients with acute myeloid leukaemia (AML) is based on 129 scientific articles: one meta-analysis, 51 randomised trials, 39 prospective and 18 retrospective studies, and 20 other articles. Altogether, 39,557 patients were included in these studies. The conclusions reached can be summarized into the following points: Standard induction therapy for patients with AML, consisting of daunorubicin and ara-C in conventional doses, results in a complete remission (CR) rate of 50-60% in an unselected population and a long-term survival of about 10-20%. The total doses of both ara-C and daunorubicin are of importance for remission duration and in some studies also for survival. High-dose ara-C in the induction therapy prolongs remission duration in randomised trials, but has not been proven to affect long-term survival. It also increases toxicity and is not generally recommended. Idarubicin, another anthracyclin, has been compared with daunorubicin in conjunction with ara-C, resulting in a higher CR rate, especially in younger patients. In a meta-analysis of the five-randomised trials performed, a slight survival advantage was also seen with idarubicin. Yet, there is inconclusive evidence to conclude that idarubicin is superior to daunorubicin, and further trials are needed. Mitoxantrone improves the outcome of induction therapy in comparison with daunorubicin in some randomised studies, but conclusive evidence is still lacking. The addition of etoposide to daunorubicin or mitoxantrone and ara-C has improved CR rates, but has not convincingly improved survival and secondary leukaemias may be induced. New induction treatment strategies are defined by identification of prognostic subgroups. A risk stratification of AML patients as to chromosomal aberrations might be of importance for the choice of therapy. Moreover, the speed and the morphological response to the first induction course are predictive for relapse. However, no prospective randomised studies are as yet published regarding risk-adapted induction therapy. Post-remission dose-intensive chemotherapy prolongs the duration of remission, seemingly most in patients < 60 years. However, the data in support of these conclusions are sparse. A convincing effect on survival has not been shown. Limited data indicate that post-remission maintenance therapy with long-term attenuated chemotherapy prolongs time to recurrence, without evidence for prolongation of survival. Allogeneic bone marrow transplantation is an established practice for consolidation in first remission for young patients with an HLA-matched sibling. It is however not known which patients will really benefit from transplantation as no truly randomised comparison of allogeneic vs autologous transplantation or conventionally-dosed chemotherapy has been performed. Patients with and without an HLA-identical sibling have been compared on the basis of intention-to-treat principles ('genetic randomisation'). The disease-free survival seems to be prolonged in the donor group, due to a lower relapse rate with allogeneic transplantation. A higher procedure-related mortality makes the effects on total survival uncertain. Randomised trials with autologous transplantation vs conventional consolidation show a lower relapse rate and a trend for an improved disease-free survival. In one study, in which an autograft was added to four courses of intensive therapy, there was also a late survival advantage. Thus, the role for intensified post-remission treatment in first complete remission with high-dose chemotherapy followed by allogeneic or autologous marrow or stem cell transplantation requires further studies. Moreover, studies with stratification of therapy according to predictors for prognosis in the individual patient are needed. Allogeneic stem cell transplantation after minimal or reduced myeloablative conditioning ('mini-transplantation' or non-myelo stem cell transplantation) induces a host-vs-graft tolerance and an immune graft-vs-leukaemia effect. This new concept of immunotherapy seems to have a low procedure-related mortality, but long-term effects are unknown and evaluation in controlled clinical studies is required. Patients with relapsed AML can only infrequently achieve long-term remissions with chemotherapy in conventional doses. trolled data indicate that allogeneic transplantation can be a curative treatment for these patients a" @default.
• W2138906968 created "2016-06-24" @default.
• W2138906968 creator A5001084766 @default.
• W2138906968 creator A5044651904 @default.
• W2138906968 creator A5065902991 @default.
• W2138906968 date "2001-03-01" @default.
• W2138906968 modified "2023-10-16" @default.
• W2138906968 title "A Systematic Overview of Chemotherapy Effects in Acute Myeloid Leukaemia" @default.
• W2138906968 cites W107098111 @default.
• W2138906968 cites W1143126211 @default.
• W2138906968 cites W118967028 @default.
• W2138906968 cites W1274344746 @default.
• W2138906968 cites W1479909146 @default.
• W2138906968 cites W1481564836 @default.
• W2138906968 cites W1492445977 @default.
• W2138906968 cites W1492877482 @default.
• W2138906968 cites W1493398929 @default.
• W2138906968 cites W151316131 @default.
• W2138906968 cites W1519562949 @default.
• W2138906968 cites W1534965621 @default.
• W2138906968 cites W1561447878 @default.
• W2138906968 cites W1585733692 @default.
• W2138906968 cites W1586473141 @default.
• W2138906968 cites W1586763410 @default.
• W2138906968 cites W1591796471 @default.
• W2138906968 cites W1605880824 @default.
• W2138906968 cites W1629163346 @default.
• W2138906968 cites W1704551630 @default.
• W2138906968 cites W1709114039 @default.
• W2138906968 cites W1823520599 @default.
• W2138906968 cites W1835148062 @default.
• W2138906968 cites W1849389269 @default.
• W2138906968 cites W1860795225 @default.
• W2138906968 cites W1860800305 @default.
• W2138906968 cites W1861929829 @default.
• W2138906968 cites W1870350942 @default.
• W2138906968 cites W1909698311 @default.
• W2138906968 cites W1934064433 @default.
• W2138906968 cites W1941946666 @default.
• W2138906968 cites W1963335440 @default.
• W2138906968 cites W1965979673 @default.
• W2138906968 cites W1966831768 @default.
• W2138906968 cites W1969474912 @default.
• W2138906968 cites W1979969603 @default.
• W2138906968 cites W1985781809 @default.
• W2138906968 cites W1989243248 @default.
• W2138906968 cites W1991058838 @default.
• W2138906968 cites W1993561248 @default.
• W2138906968 cites W1996389468 @default.
• W2138906968 cites W2000275771 @default.
• W2138906968 cites W2000838340 @default.
• W2138906968 cites W2004315434 @default.
• W2138906968 cites W2013051826 @default.
• W2138906968 cites W2017513591 @default.
• W2138906968 cites W2019793347 @default.
• W2138906968 cites W2021929491 @default.
• W2138906968 cites W2023555617 @default.
• W2138906968 cites W2039082386 @default.
• W2138906968 cites W2039412651 @default.
• W2138906968 cites W2047435984 @default.
• W2138906968 cites W2047544549 @default.
• W2138906968 cites W2048312112 @default.
• W2138906968 cites W2051232892 @default.
• W2138906968 cites W2054037962 @default.
• W2138906968 cites W2074222658 @default.
• W2138906968 cites W2083600033 @default.
• W2138906968 cites W2090276004 @default.
• W2138906968 cites W2090585991 @default.
• W2138906968 cites W2098854099 @default.
• W2138906968 cites W2105643967 @default.
• W2138906968 cites W2109492470 @default.
• W2138906968 cites W2112667410 @default.
• W2138906968 cites W2113367077 @default.
• W2138906968 cites W2131135213 @default.
• W2138906968 cites W2136781769 @default.
• W2138906968 cites W2152363012 @default.
• W2138906968 cites W2152823289 @default.
• W2138906968 cites W2176980523 @default.
• W2138906968 cites W2191003384 @default.
• W2138906968 cites W2201158929 @default.
• W2138906968 cites W2204518675 @default.
• W2138906968 cites W2211072972 @default.
• W2138906968 cites W2228456847 @default.
• W2138906968 cites W2239373244 @default.
• W2138906968 cites W2252759819 @default.
• W2138906968 cites W2315152253 @default.
• W2138906968 cites W2318674152 @default.
• W2138906968 cites W2339692928 @default.
• W2138906968 cites W2394498723 @default.
• W2138906968 cites W2398077016 @default.
• W2138906968 cites W2403964029 @default.
• W2138906968 cites W2406249232 @default.
• W2138906968 cites W2408301256 @default.
• W2138906968 cites W2409849732 @default.
• W2138906968 cites W2410122496 @default.
• W2138906968 cites W2412055789 @default.
• W2138906968 cites W2413164329 @default.
• W2138906968 cites W2413869846 @default.

• next